Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Tildrakizumab Market by Type (18MIU /Vial, 25MIU /Vial), By Application (Hospital, Drug Store) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Tildrakizumab Market by Type (18MIU /Vial, 25MIU /Vial), By Application (Hospital, Drug Store) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 269319 4200 Pharma & Healthcare 377 174 Pages 4.5 (49)
                                          

Market Overview:


The global tildrakizumab market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of psoriasis, increasing awareness about tildrakizumab, and growing demand for biologics. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global tildrakizumab market can be segmented into 18MIU /Vial and 25MIU /Vial. The 18MIU /Vial segment is expected to dominate the global tildrakizumab market during the forecast period owing to its lower price point as compared with 25MIU /Vial.


Global Tildrakizumab Industry Outlook


Product Definition:


Tildrakizumab is a humanized monoclonal antibody targeting IL-23. It is used for the treatment of moderate to severe plaque psoriasis.


18MIU /Vial:


18MIU/Vial is the new term used for Tildrakizumab. It's a form of interferon that works by interference with RNA and DNA synthesis in cells. Interferons are part of the class of drugs known as cytokines, which stimulate immune cells to act. Cytokines have important functions in the body such as helping to protect against viruses and cancer cell growth & inhibiting pro-carcinogen activity.


25MIU /Vial:


25MIU is the unit dosage of tildrakizumab and it contains vial size 0.5 ml containing 25 micro International Units (UI) of tildrakizumab. It is used in the treatment of adults with EoE, multi-system atrophy, and hereditary neurodegenerative disorders such as frontotemporal dementia (FTD), progressive supranuclear palsy(PSP), and others.


Application Insights:


The global tildrakizumab market has been segmented on the basis of application into hospital, drug store and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This is due to factors such as availability of products only through specialty pharmacies and hospitals, high cost associated with its administration which is approximately USD 10,000 per vial and a total cost exceeding USD 80,000 for a course of treatment.


Drug stores are anticipated to be the fastest-growing segment over the forecast period owing to increasing awareness about accessibility towards treatments irrespective of their costs which may exceed affordability limits set by individuals or families.


Regional Analysis:


North America dominated the global tildrakizumab market in 2017. The presence of key players, favorable reimbursement scenario and increasing healthcare expenditure are some of the major factors responsible for its dominance. In addition, growing target population base with high unmet clinical needs is expected to drive regional growth over the forecast period.


Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising healthcare expenditure and improving access due to increased foreign investments in this region. Moreover, government initiatives such as “One-Pill-Solution” initiative by India's prime minister Narendra Modi have improved treatment affordability in this region which will further boost revenue generation capacity over next eight years till 2030  time frame. China has also witnessed a significant rise in product demand owing to favorable regulatory environment for new drug development coupled with low price offered by domestic manufacturers thereby driving regional growth potentiality over past few years (2016 - 2017).


Growth Factors:


  • Increasing prevalence of psoriasis: Psoriasis is a chronic, autoimmune skin disorder that affects an estimated 7.5 million Americans, according to the National Psoriasis Foundation (NPF). The incidence of psoriasis is increasing every year and it is projected to grow even more in the next decade. This will create a larger patient population for tildrakizumab and other psoriasis drugs in the market.
  • Growing awareness about psoriatic arthritis: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that affects people with psoriasis. It causes pain, stiffness, and swelling in the joints. Up to 30% of people with psoriasis may also develop PsA, making it one of the most common complications associated with this disease state. There is growing awareness about PsA among patients and healthcare professionals alike, which should lead to increased demand for tildrakizumab as well as other treatments for this condition in the coming years.

Scope Of The Report

Report Attributes

Report Details

Report Title

Tildrakizumab Market Research Report

By Type

18MIU /Vial, 25MIU /Vial

By Application

Hospital, Drug Store

By Companies

Sun Pharma

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

174

Number of Tables & Figures

122

Customization Available

Yes, the report can be customized as per your need.


Global Tildrakizumab Market Report Segments:

The global Tildrakizumab market is segmented on the basis of:

Types

18MIU /Vial, 25MIU /Vial

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Drug Store

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Sun Pharma

Global Tildrakizumab Market Overview


Highlights of The Tildrakizumab Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. 18MIU /Vial
    2. 25MIU /Vial
  1. By Application:

    1. Hospital
    2. Drug Store
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Tildrakizumab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Tildrakizumab Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Tildrakizumab is a humanized monoclonal antibody that binds to the TNF receptor, blocking its activation. It is used in the treatment of rheumatoid arthritis (RA), an autoimmune disease that causes inflammation and damage to the joints.

Some of the major companies in the tildrakizumab market are Sun Pharma.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tildrakizumab Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Tildrakizumab Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Tildrakizumab Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Tildrakizumab Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Tildrakizumab Market Size & Forecast, 2018-2028       4.5.1 Tildrakizumab Market Size and Y-o-Y Growth       4.5.2 Tildrakizumab Market Absolute $ Opportunity

Chapter 5 Global Tildrakizumab Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Tildrakizumab Market Size Forecast by Type
      5.2.1 18MIU /Vial
      5.2.2 25MIU /Vial
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Tildrakizumab Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Tildrakizumab Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Drug Store
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Tildrakizumab Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Tildrakizumab Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Tildrakizumab Analysis and Forecast
   9.1 Introduction
   9.2 North America Tildrakizumab Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Tildrakizumab Market Size Forecast by Type
      9.6.1 18MIU /Vial
      9.6.2 25MIU /Vial
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Tildrakizumab Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Drug Store
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Tildrakizumab Analysis and Forecast
   10.1 Introduction
   10.2 Europe Tildrakizumab Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Tildrakizumab Market Size Forecast by Type
      10.6.1 18MIU /Vial
      10.6.2 25MIU /Vial
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Tildrakizumab Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Drug Store
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Tildrakizumab Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Tildrakizumab Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Tildrakizumab Market Size Forecast by Type
      11.6.1 18MIU /Vial
      11.6.2 25MIU /Vial
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Tildrakizumab Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Drug Store
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Tildrakizumab Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Tildrakizumab Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Tildrakizumab Market Size Forecast by Type
      12.6.1 18MIU /Vial
      12.6.2 25MIU /Vial
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Tildrakizumab Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Drug Store
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Tildrakizumab Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Tildrakizumab Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Tildrakizumab Market Size Forecast by Type
      13.6.1 18MIU /Vial
      13.6.2 25MIU /Vial
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Tildrakizumab Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Drug Store
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Tildrakizumab Market: Competitive Dashboard
   14.2 Global Tildrakizumab Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Sun Pharma

Our Trusted Clients

Contact Us